Loading
Latest filing published 15 Apr 2026 for Marinomed Biotech AG, €4,998.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Eva Prieschl-Grassauer, listed as chief executive, appears in our data through filings on Marinomed Biotech AG shares, published by FMA (OeKB OAM). Between 31 March 2026 and 13 April 2026, the trades on record add up to 2 filings.
The open-market record is one-sided, with 1 purchase worth €4,998 and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.
Most recently, on 15 April 2026, the filings show an open-market purchase worth €4,998 in Marinomed Biotech AG. Source: insider filings from FMA (OeKB OAM). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations